Abstract
High rates of pertussis disease in adolescents suggest that additional boosting against pertussis would be beneficial. A combined acellular-pertussis-containing booster vaccine (dTpa-IPV; Boostrix™ Polio, n =440) was compared to separately administered dTpa (Boostrix™) and inactivated polio virus (IPV; Imovax Polio®, n =219), and to DTPa-IPV (Infanrix™ IPV, n =111) vaccine in a partially blind, randomised controlled trial in 10–14 year olds. One month after vaccination, seroprotection/seropositivity rates for all antigens were similar for all groups. Although pertussis and diphtheria antibody geometric mean antibody concentrations were higher after DTPa-IPV, all subjects had protective antibodies against diphtheria, tetanus and polio, and at least 97% had a vaccine response to pertussis antigens. Reactogenicity of dTpa-IPV was comparable to dTpa + IPV, but dTpa-IPV was generally better tolerated than DTPa-IPV. Conclusion:The combined reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and IPV vaccine is immunogenic and well tolerated when administered to adolescents and could be used to improve the control of pertussis disease in this age group.
Similar content being viewed by others
Abbreviations
- CI :
-
confidence interval
- DTPa :
-
diphtheria, tetanus and acellular pertussis vaccine
- DTPw :
-
diphtheria, tetanus and whole-cell pertussis vaccine
- dTpa-IPV :
-
dTpa-IPV reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and IPV vaccine
- GMC :
-
geometric mean antibody concentration
- IPV :
-
inactivated polio virus
- dTpa :
-
reduced-antigen-content-diphtheria-tetanus and acellular pertussis vaccine
References
Aoyama T, Harashima M, Nishimura K, Saito Y (1995) Outbreak of pertussis in highly immunized adolescents and its secondary spread to their families. Acta Pediatr Japn 37: 321–324
Bonmarin I, Laurent E, Guiso N, Levy-Bruhl D, Renacoq (2003) Surveillance de la coqueluche à l’hopital en 2001. Bulletin Epidémiologique Hebdomadaire 44: 213–214
Bulletin Epidémiologique Hebdomadaire (2003) Calendrier vaccinal 2003 Avis du Conseil supérieur d’hygiène publique de France 06: 33–37
Cattaneo L, Reed G, Haase D, Wills M, Edwards K (1996) The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years. J Infect Dis 173: 1256–1259
Campins-Marti M, Cheng HK, Forsyth K, Guiso N, Halperin S, Huang L-M, Mertsola J, Oselka G, Ward J, Wirsing von König CH, Zepp F (2002) Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 20: 641–646
Centers for Disease Control and Prevention (2002) Pertussis—United States, 1997–2000. MMWR 51: 73–76
Dagan R, Igbaria K, Piglansky L, Melamed R, Willems P, Grossi A, Kaufhold A (1997) Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatr Infect Dis J 16: 1113–1121
Gil A, Oyagüez I, Carrasco P, González A (2001) Hospital admissions for pertussis in Spain, 1995–1998. Vaccine 19: 4791–4794
Grimprel E, Baron S, Levy-Bruhl D, Garnier JM, N’jamkepo E, Guiso N, Bégué P (1999) Influence of vaccination coverage on pertussis transmission in France. Lancet 354: 1699–1770
Gylca R, Gylca V, Benes O, Melnic A, Chicu V, Weisbecker C, Willems P, Kaufhold A (2000) A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks following HBV at birth. Vaccine 19: 825–833
He Q, Viljanen M, Arvilommi H, Aittanen B, Mertsola J (1998) Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA 280: 635–637
Izurieta H, Kenyon T, Strebel P, Baughman A, Shulman S, Wharton M (1996) Risk factors for pertussis in young infants during an outbreak in Chicago in 1993. Clin Infect Dis 22: 503–507
Lin M, Roche P, Spencer J, Milton A, Wright P, Witteveen D, Leader R, Merianos A, Bunn C, Gidding H, Kaldor J, Kirk M, Hall R, Della-Porta T (2002) Australia’s notifiable disease status, 2000: annual report of the national notifiable diseases surveillance system. Commun Dis Intell 26: 118–203
McIntyre P, Gidding H, Gilmour R, Lawrence G, Hull B, Horby P, Wang H, Andrews R, Burgess M (2002) Vaccine preventable diseases and vaccination coverage in Australia, 1999 to 2000. Commun Dis Intell [Suppl I-XI]: 1–111
Mertsola J (2001) Has pertussis been tamed? Duodecim 117: 1101–1108
Morris A, Elliott E, McIntyre P, Massie J, Ridley G, McEniery J, Knight G and Contributors to the Australian Paediatric Surveillance Unit (APSU) (2002) Hospitalized pertussis in infancy. J Pediatr Child Health 38: A2
Nennig ME, Shinefield H, Edwards K, Black S, Fireman B (1996) Prevalence and incidence of adult pertussis in an urban population. JAMA 275: 1672–1674
Pichichero M, Deloria M, Rennels M, Anderson E, Edwards K, Decker M, Englund J, Steinhoff M, Deforest A, Meade B (1997) A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given a fourth dose in 15- to 20-month-old children. Pediatrics 100: 772–788
Schmitt HJ, Schuind A, Knuf M, Beutel K, Schulte-Wissermann H, Gahr M, Schult R, Folkens J, Rauh W, Bogaerts H, Bock HL, Clemens R (1996) Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22, 505 infants. J Pediatr 129: 695–701
Schmitt H, von König C, Neiss A, Bogaerts H, Bock HL, Schulte-Wissermann H, Gahr M, Schult R, Folkens JU, Rauh W, Clemens R (1996) Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 275: 37–41
Skowronski D, De Serres G, MacDonald D, Wu W, Shaw C, Macnabb J, Champagne S, Patrick DM, Halperin SA (2002) The changing age and seasonal profile of pertussis in Canada. J Infect Dis 185: 1448–1453
Stojanov S, Liese J, Belohradsky B (2000) Hospitalization and complications in children under 2 years of age with Bordetella pertussis infection. Infection 28: 106–110
Vitek C, Pascual F, Baughman A, Murphy T (2003) Increase in deaths from pertussis among young infants in the United States in the 1990s. Pediatr Infect Dis J 22: 628–634
World Health Organization (2003) Vaccines, immunization and biologicals: pertussis vaccine (WHO-Vaccines, immunization and biologicals web site)http://www.who.int/vaccines/en/pertussis.shtml
Zepp F, Cheuvart B, Wolter J (2003) Anti-diphtheria antibodies should persist until adolescence after a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (dTpa) in pre-school-aged children (abstract). 21st Annual Meeting of the European Society for Pediatric Infectious Diseases, Taormina Sicily, April 9-11
Acknowledgements
This study was supported by GlaxoSmithKline Biologicals, Rixensart, Belgium.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vergara, R., Tregnaghi, M., Ussher, J. et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 164, 377–382 (2005). https://doi.org/10.1007/s00431-005-1650-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-005-1650-y